EGRX Eagle Pharmaceuticals Inc
Price (delayed)
$4.29
Market cap
$55.71M
P/E Ratio
4.66
Dividend/share
N/A
EPS
$0.92
Enterprise value
$110.55M
Eagle Pharmaceuticals Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements
Highlights
Eagle Pharmaceuticals's quick ratio has increased by 35% YoY and by 8% from the previous quarter
The company's equity rose by 6% YoY and by 3.8% QoQ
Eagle Pharmaceuticals's debt has increased by 41% YoY but it has decreased by 8% QoQ
Eagle Pharmaceuticals's gross margin has decreased by 5% YoY but it has increased by 2% from the previous quarter
The EPS has contracted by 50% YoY
The net income has declined by 48% year-on-year
Key stats
What are the main financial stats of EGRX
Market
Valuations
Earnings
Shares outstanding
12.99M
Market cap
$55.71M
Enterprise value
$110.55M
Price to earnings (P/E)
4.66
Price to book (P/B)
0.22
Price to sales (P/S)
0.22
EV/EBIT
3.14
EV/EBITDA
1.93
EV/Sales
0.43
Revenue
$257.55M
EBIT
$35.26M
EBITDA
$57.18M
Free cash flow
-$9.39M
Per share
Balance sheet
Liquidity
EPS
$0.92
Free cash flow per share
-$0.72
Book value per share
$19.25
Revenue per share
$19.67
TBVPS
$19.28
Total assets
$404.82M
Total liabilities
$152.78M
Debt
$70.19M
Equity
$252.04M
Working capital
$100.62M
Debt to equity
0.28
Current ratio
2.16
Quick ratio
1.51
Net debt/EBITDA
0.96
Margins
Efficiency
Dividend
EBITDA margin
22.2%
Gross margin
69.8%
Net margin
4.6%
Operating margin
15.9%
Return on assets
3%
Return on equity
5%
Return on invested capital
19.3%
Return on capital employed
11.1%
Return on sales
13.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EGRX stock price
How has the Eagle Pharmaceuticals stock price performed over time
Intraday
-0.46%
1 week
10%
1 month
-5.3%
1 year
-73.53%
YTD
-17.97%
QTD
-23.39%
Financial performance
How have Eagle Pharmaceuticals's revenue and profit performed over time
Revenue
$257.55M
Gross profit
$179.88M
Operating income
$41.01M
Net income
$11.95M
Gross margin
69.8%
Net margin
4.6%
The net income has declined by 48% year-on-year
Eagle Pharmaceuticals's net margin has decreased by 45% YoY
Eagle Pharmaceuticals's operating income has decreased by 29% YoY but it has increased by 25% QoQ
The operating margin is up by 29% since the previous quarter but it has declined by 25% year-on-year
Growth
What is Eagle Pharmaceuticals's growth rate over time
Valuation
What is Eagle Pharmaceuticals stock price valuation
P/E
4.66
P/B
0.22
P/S
0.22
EV/EBIT
3.14
EV/EBITDA
1.93
EV/Sales
0.43
The EPS has contracted by 50% YoY
EGRX's P/B is 92% below its 5-year quarterly average of 2.9 and 84% below its last 4 quarters average of 1.4
The company's equity rose by 6% YoY and by 3.8% QoQ
EGRX's price to sales (P/S) is 92% lower than its 5-year quarterly average of 2.8 and 82% lower than its last 4 quarters average of 1.2
The company's revenue fell by 5% YoY and by 3.6% QoQ
Efficiency
How efficient is Eagle Pharmaceuticals business performance
The ROS has soared by 90% from the previous quarter but it has contracted by 12% YoY
EGRX's return on invested capital has surged by 61% since the previous quarter but it has dropped by 55% year-on-year
Eagle Pharmaceuticals's ROA has plunged by 60% YoY
Eagle Pharmaceuticals's return on equity has shrunk by 55% YoY
Dividends
What is EGRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EGRX.
Financial health
How did Eagle Pharmaceuticals financials performed over time
Eagle Pharmaceuticals's total assets is 165% higher than its total liabilities
Eagle Pharmaceuticals's quick ratio has increased by 35% YoY and by 8% from the previous quarter
EGRX's current ratio is up by 21% YoY and by 10% QoQ
Eagle Pharmaceuticals's debt is 72% lower than its equity
Eagle Pharmaceuticals's debt has increased by 41% YoY but it has decreased by 8% QoQ
Eagle Pharmaceuticals's debt to equity has increased by 33% YoY but it has decreased by 10% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.